Adaptive Biotechnologies Corp
ADPTQ3 2025(ADPT Q2 FY2025)Derived8% AI
AI Revenue %
8%
AI Fair Value
$144.7M
AI Revenue (Q)
$6.8M
Total Revenue (Q)
$85.1M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Total revenue $58.9M. MRD: $49.9M. Immune Medicine: $8.9M. MRD continues strong growth. IM steady at ~$9M (no milestone). Applying 50% AI attribution to IM: $8.9M * 50% = $4.5M. AI Revenue % = $4.5M / $58.9M = 7.6%, rounded to 8%. IM's share of total revenue declining as MRD outpaces it.
Analyzed by claude-opus-4-6
Quoted Figures
MRD Revenue $49,938K, Immune Medicine Revenue $8,941K, Total $58,879K for Q2 2025
10-Q filed 2025-08-06, Segment Information note
AI Products Identified (Ring 1)
TCR-Antigen Map (AI/ML-driven immune receptor-disease mapping)Adaptive Immunosequencing (AI/ML analysis)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic test ($49.9M MRD segment)MRD Pharma testing services
Confidence Tier
DerivedCalculated from reported segments primarily serving AI